Research Supported by our Foundation

RESEARCH SUPPORTED BY OUR FOUNDATION

Our foundation has granted over $7.5 million, leading to groundbreaking therapies. 

We have supported over 55 studies to help scientists investigate probable approaches to improve treatment and develop a cure.

ALL RESEARCH STUDIES SUPPORTED BY OUR FOUNDATION

Below is a comphrensive list of research we have funding since we began in 2002.  If you are interested in applying for a grant, please download the application guidelines.

Studies Funded in 2019

  • .
  • Researcher
  • Institution
  • 2019 Granted Projects
  • Dr. Junho Cho
  • University of Connecticut
  • Evaluation of the strategy for autophagy normalization to prevent HCA/HCC in glycogen storage disease type 1a.

    $199,056.00


  • Dr. Youngmok Lee
  • University of Connecticut
  • Exosome marker development for hepatocellular adenoma in human GSD1a & Development of kidney direct gene therapy in GSD-1a mice.

    $357,667.00


  • Dr. Janice Chou
  • NIH
  • Evaluate the efficiency of CRISPR/Cas9-based gene editing system to correct a G6PC mutation in an animal model of GSD 1a.

    $226,720.00


  • Heather Saavedra
  • University of Texas
  • Support of gene therapy trials

    $7,200.00


  • Dr. David Weinstein
  • University of Connecticut
  • Support of gene therapy trials

    $15,000.00


  • Dr. Ayesha Ahmad
  • University of Michigan
  • Support of gene therapy trials

    $7,200.00


Studies Funded in 2018

  • .
  • Researcher
  • Institution
  • 2018 Granted Projects
  • Dr. Youngmok Lee
  • University of Connecticut
  • Exosome marker development for hepatocellular adenoma in human GSD1a

    $37,039.00


  • Dr. David Weinstein
  • University of Connecticut
  • Evaluation of the efficacy of gene therapy to arrest or abrogate the preexisting hepatocellular adenoma/carcenoma in glycogen storage disease type 1a

    $153,011.00


  • Dr. Janice Chou
  • NIH
  • Evaluate the efficacy of CRISPR/Cas9-based gene editing system to correct a G6PC mutation in an animal model of GSD 1a

    $160,040.00


  • Dr. Youngmok Lee
  • University of Connecticut
  • Research development to improve the efficacy of AAV mediated gene therap in GSD1a mouse model

    $370,326 (over 2 years)


  • Dr. Mitchell Drumm
  • Case Western Reserve University
  • Various GSD 1a studies

    $203,540.00


  • Dr. David Weinstein
  • University of Connecticut
  • Evaluation of the efficacy of gene therapy to arrest or abrogate the preexisting hepatocellular adenoma/carcinoma in glycogen storage disease type 1a. Colony

    $153,011.00


Studies Funded in 2017

  • .
  • Researcher
  • Institution
  • 2017 Granted Projects
  • Dr. Thomas Conlon
  • University of Florida
  • Colony maintenance of glycogen storage disease type 1a canines treated with AAV gene therapy

    $121,395.00


  • Dr. Janice Chou
  • NIH
  • Evaluate the efficiency of CRISPR/Cas9-based gene editing system to correct a G6PC mutation in an animal model of GSD 1a

    $152,850.00


  • Dr. Youngmok Lee
  • Univesity of Connecticut
  • Development of kidney direct gene therapy in GSD 1a mice

    $158,329.00


Studies Funded in 2016

  • .
  • Researcher
  • Institution
  • 2016 Granted Projects
  • Dr. Janice Chou
  • NIH
  • Development of Gene Therapy Vectors for GSD 1a with improved efficacy

    $147,220.00


Studies Funded in 2015

  • .
  • Researcher
  • Institution
  • 2015 Granted Projects
  • Dr. Janice Chou
  • NIH
  • Evaluation of the efficacy of AAV8-GPE in GSD-la mice with pre-existing hepatocellular adenoma

    $89,020.00


Studies Funded in 2014

  • .
  • Researcher
  • Institution
  • 2014 Granted Projects
  • Dr. William Fodor
  • GlyGenix Theurapedics, Inc.
  • Chemistry, Manufacturing and Controls: Ensuring AAV2/8-G6Phase is produced to meet FDA Standardss Suitable for Toxicology and Clinical Studies

    $104,000.00


  • Dr. Nataly Clement
  • University of Florida
  • $38,368.00


  • Dr. Janice Chou
  • NIH
  • Evaluation of the efficacy of of AAV8-GPW in GSD-1a mice with pre-existing hepotacellular adenoma

    $106,306.00


Studies Funded in 2013

  • .
  • Researcher
  • Institution
  • 2013 Granted Projects
  • Dr. David Weinstein, Dr. Thomas Conlon
  • University of Florida
  • Gene Therapy for Glycogen Storage Disease, Type 1a

    $156,083.00


  • Dr. Janice Chou
  • NIH
  • Evaluation of the efficacy of a recombinant AAV vector expressing the condon-optimized human G6Phase

    $98,996.00


Studies Funded in 2012

  • .
  • Researcher
  • Institution
  • 2012 Granted Projects
  • Dr. Janice Chou
  • NIH
  • Evaluation of the efficacy of AAV8-GPE in GSD1a mice with pre-existing hepatocelluar adenoma

    $95,846.00


  • Dr. Thomas Conlon, Dr. David Weinstein, Dr. Barry Byrne
  • University of Florida
  • Gene Therapy for GSD1

    $117,508.00


  • Dr. Janice Chou
  • NIH
  • The Evaluation of the efficacy of two AAV vectors in murine GSD1a

    $44,264.50


  • Dr. Dwight Koeberl
  • Duke University
  • The Evaluation of the efficacy of two AAV vectors in murine GSD1a

    $55,016.50


Studies Funded in 2011

  • .
  • Researcher
  • Institution
  • 2011 Granted Projects
  • Dr. Janice Chou
  • NIH
  • The Evaluation of the efficacy of two AAV vectors in murine GSD1a

    $88,529.00


  • Dr. Dwight Koeberl
  • Duke University
  • The Evaluation of the efficacy of two AAV vectors in murine GSD1a

    $110,033.00


  • Dr. Janice Chou
  • NIH
  • Long-term consequences of AAV-mediated gene therapy for GSD1a

    $93,936.00


Studies Funded in 2010

  • .
  • Researcher
  • Institution
  • 2010 Granted Projects
  • Dr. Dwight Koeberl
  • Duke University
  • Pre-Clinical Development of AAV vectors for Gene Therapy in GSD1a

    $167,087.00


  • Dr. Thomas Conlon Dr. David Weinstein, Dr. Barry Byrne
  • University of Florida
  • Gene Therapy for GSD1a

    $570,553(over 2 years)


Studies Funded in 2009

  • .
  • Researcher
  • Institution
  • 2009 Granted Projects
  • Dr. David Weinstein/Dr. Priya Kishnani
  • University of Florida/Duke University
  • A multicenter, double blind crossover study of the dosing and efficiency of modified resistant cornstarch in GSD1a patients

    $54,541.00


  • Dr. Thomas Conlon/Dr. Catherine Mah
  • University of Florida
  • Gene Therapy for GSD1a

    $100,000.00


  • Dr. Dwight Koeberl/Dr. Carlos Pinto
  • Duke Universtiy
  • Pre-clinical development of a highly effecacious AAV vector in GSD1a dogs

    $23,049.00


Studies Funded in 2008

  • .
  • Researcher
  • Institution
  • 2008 Granted Projects
  • Dr. Janice Chou
  • NIH
  • Long-term consequences of AAV-mediated gene therapy for GSD-Ia.

    $74,030.00


  • Dr. Howard Sussman
  • Stanford University
  • Identification of Pharmaceutical Targets for Hepatic Adenoma in GSD1a

    $97,748.00


  • Dr. Dwight Koeberl
  • Duke Universtiy
  • Development of AAV Vectors for GSD1a

    $67,159.00


Studies Funded in 2007

  • .
  • Researcher
  • Institution
  • 2007 Granted Projects
  • Dr. Lawrence Chan
  • Baylor College of Medicine
  • Curative Treatment for GSD1a in a Dog Model

    $183,222 (over 2 years)


  • Dr. Janice Chou
  • NIH
  • Renal Disease in GSD 1a

    $55,365.00


  • Dr. Cathryn Mah
  • University of Florida
  • Gene Therapy for GSD1a

    $499,538 (over 2 years)


  • Dr. Carlos Pinto
  • NC State College of Veterinary Medicine
  • Pre-Clinical Development of a Highly Efficacious AAV Vector in GSD1a Dogs

    $251,211 (over 2 years)


  • Dr. Howard Sussman
  • Stanford University
  • Identification of Pharmaceutical Targets for Hepatic Adenoma in GSD1a

    $95,091.00


  • Drs. Priya Kishnani and David Weinstein
  • Duke University and University of Florida
  • A multicenter, double-blind crossover study of the dosing and efficiency of modified resistant cornstarch in patients with GSD1a.

    $249,382 (over 15 months)


Studies Funded in 2006

  • .
  • Researcher
  • Institution
  • 2006 Granted Projects
  • Dr. Bryon Peterson, PhD
  • University of Florida College of Medicine
  • Gene/Stem Cell Therapy for the correction of GSD1 Disease

    $124,797.00


  • Dr. Carlos Pinto, DVM, PhD
  • North Carolina State University, College of Veterinary Medicine
  • Long-term correction of canine GSD1a using AAV2/8 vectors and toxicity of helper-dependent and AAV viral vectors

    $86,049.00


  • Dr. Dwight Koeberl, MD, PhD
  • Duke University Medical Center
  • Preclinical Development of AAV vectors for gene therapy in GSD1a and the evaluation of the long-term safety and efficacy of AAV vectors in the available animal models.

    $157,658 (over 2 years)


  • Dr. Howard Sussman, MD
  • Stanford University Medical Center
  • Identification of pharmaceutical targets for hepatic adenoma in GSD1a

    $130,724 (over 2 years)


Studies Funded in 2005

  • .
  • Researcher
  • Institution
  • 2005 Granted Projects
  • Dr. Janice Chou and Mohammad Allamarvdasht
  • National Institutes of Health, Bethesda, Maryland
  • Recombinant adeno-associated virus-mediated gene therapy for glycogen storage disease type 1 directed by the human glucose-6-phosphatase promoter

    $158,300.00


  • Dr. David Weinstein
  • University of Florida, Dept. of Pediatrics
  • An open-label, crossover study of alternative dietary therapies for GSD, Type 1

    $153,442.00


  • Drs. Priya Kishnani and Deeksha Bali
  • Duke University Medical Center
  • Clinical and Molecular Evaluations in Glycogen Storage Disease Type 1a

    $169,248.00


  • Dr. Talmage Brown
  • North Carolina State Univ., College of Veterinary Medicine
  • Long-term Correction of Canine GSD1a using AAV2/8 Vectors

    $111,809.00


  • Bryon Petersen, Ph.D
  • University of Florida, College of Medicine
  • Gene/Stem Cell Therapy for the Correction of GSD1 Patients

    $125,175.00


  • Drs. Cathryn Mah and Barry Byrne
  • University of Florida, College of Medicine
  • Gene Therapy for Glycogen Storage Disease Type 1a

    $155,285.40


Studies Funded in 2004

  • .
  • Researcher
  • Institution
  • 2004 Granted Projects
  • Drs. Reba Condiotti and Ethan Galun in collaboration with Drs. Janice Chou and Shimon Moses
  • Goldyne Savad Institute of Gene Therapy, Hadassah University Hospital Jerusalem, Israel NIH Bethesda, Maryland Soroka Medical Center Beersheva, Israel
  • Use of a non-primate lentiviral vector for stable and prolonged G6Pase espression for therapy of GSD1a

    $145,000.00


  • Drs. Dwight Koeberl and Haoyue Zhang, Ayn Schneider and Andrew Bird
  • Duke University Medical Center North Carolina
  • Regulated G6Pase expression with AAV vectors to correct GSD1a

    $183,310.00


  • Dr. G.P.A. Smit and Danielle Martens
  • Beatrix Children's Hosptial, University Hospital Groningen, The Netherlands
  • ISGSD1 project and patient database

    $32,400.00


  • Drs. David Weintstein, Emanuela Gussoni, Mark Flemming and Morey Haymond
  • Children's Hosptial Boston Harvard Medical School Boston
  • Quantification of Endogenous Glucose Production as a Marker of Glucose-6-Phosphatase Activity after Bone Marrow Transplantation

    $76,558.00


Studies Funded in 2003

  • .
  • Researcher
  • Institution
  • 2003 Granted Projects
  • Drs. David Weinstein, David Breault, and William Tse
  • Children's Hospital Boston
  • Use of Bone Marrow Derived Stem Cells to Correct Glucose-6-Phosphatase Activity in Type 1a Glycogen Storage Disease

    $50,000.00


  • Drs. Dwight Koeberl and Talmage Brown, Jr.
  • Duke University Medical Center North Carolina
  • The developement of gene therapy with AAV vectors in GSD1a

    $50,000.00


CONFIG TEMPLATE

This template controls the elements:

FOOTER: Footer Title, Footer Descriptions
CUSTOM MENU: Images and columns into header main menu submenu items

* This message is only visible in administrative mode

We may use cookies to give you the best experience on our website.
In accordance with our Privacy Policy, you hereby agree to our use of cookies on this device.